Lerociclib and Entinostat Regimens Now Cover the Full Treatment Spectrum of HR+/HER2− Advanced Breast Cancer: Inclusion in the New National Reimbursement List Enhances Access to “Effective, Safe, and Convenient” Therapies

Lerociclib and Entinostat Regimens Now Cover the Full Treatment Spectrum of HR+/HER2− Advanced Breast Cancer: Inclusion in the New National Reimbursement List Enhances Access to “Effective, Safe, and Convenient” Therapies

Hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2−) breast cancer accounts for approximately 70% of all breast cancer cases. Treatment for this subtype has entered the era of precision “endocrine plus” therapy. Endocrine therapy combined with CDK4/6 inhibitors has become the standard first-line treatment for advanced disease; however, differences in efficacy and safety exist among available agents.